Company / Depreciation & Amortization
Unicycive Therapeutics, Inc. Depreciation & Amortization History
FY2022-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$9.0K
FY2024
5-year range
$7.0K / $468.0K
FY2022-FY2024
Trend
+28.6%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $468,000 to $9,000 over the past 2 years.
Based on SEC 10-K filings.
$9,000 in FY2024.
Improved from $468,000 to $9,000 over the past 2 years.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2024, depreciation & amortization increased 28.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.91 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $9.0K | +28.6% |
| FY2023 | $7.0K | -98.5% |
| FY2022 | $468.0K | - |
As of FY2024 · SEC 10-K · Updated Jun 28, 2026